491833-25-1

Basic information

• Product Name: Eliglustat intermediate 2
• Synonyms: Eliglustat intermediate 2
• CAS NO: 491833-25-1
• Molecular Formula: C28H25NO7
• Molecular Weight: 487.5006
• Mol File: 491833-25-1.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 680.9±55.0 °C(Predicted)
• Appearance: /
• Density: 1.44±0.1 g/cm3(Predicted)
• PKA: 1.46±0.70(Predicted)
• CAS DataBase Reference: Eliglustat intermediate 2(CAS DataBase Reference)
• NIST Chemistry Reference: Eliglustat intermediate 2(491833-25-1)
• EPA Substance Registry System: Eliglustat intermediate 2(491833-25-1)

Safety Data

• Hazardous Substances Data: 491833-25-1(Hazardous Substances Data)

Usage

General Description

Eliglustat intermediate 2 is a chemical compound commonly used in the synthesis of eliglustat, an oral substrate reduction therapy for the treatment of type 1 Gaucher disease. It is a key intermediate in the manufacturing process of eliglustat and plays a crucial role in the formation of the final drug product. Eliglustat intermediate 2 is a complex organic compound with specific structural and chemical properties that make it suitable for use in the production of eliglustat. It is a vital component in the pharmaceutical industry for the creation of drugs to treat Gaucher disease, a rare genetic disorder characterized by the buildup of certain fatty substances in various organs and tissues.

Upstream product

• 29668-44-8 2,3-dihydro-benzo[1,4]dioxin-6-carbaldehyde 
• 144896-92-4 (5S)-5-phenylmorpholin-2-one 
• 20989-17-7 (2S)-2-phenylglycinol 
• 620-72-4 phenyl 2-bromoacetate 
• 491833-36-4 (S)-5-phenylmorpholin-2-one hydrochloride 

Downstream Products

• 491833-28-4 (1R,2R)-2-amino-1-(2,3-dihydrobenzo[β][1,4]dioxin-6-yl)-3-pyrrolidin-1-yl-propan-1-ol 
• 491833-29-5 (1R,2R)-octanoic acid [2-(2',3'-dihydro-benzo[1,4]dioxin-6'-yl)-2-hydroxy-1-pyrrolidin-1-ylmethyl-ethyl]-amide 

Relevant articles and documents

Optimization of Eliglustat-Based Glucosylceramide Synthase Inhibitors as Substrate Reduction Therapy for Gaucher Disease Type 3

There remain no approved therapies for rare but devastating neuronopathic glyocosphingolipid storage diseases, such as Sandhoff, Tay-Sachs, and Gaucher disease type 3. We previously reported initial optimization of the scaffold of eliglustat, an approved therapy for the peripheral symptoms of Gaucher disease type 1, to afford 2, which effected modest reductions in brain glucosylceramide (GlcCer) in normal mice at 60 mg/kg. The relatively poor pharmacokinetic properties and high Pgp-mediated efflux of 2 prompted further optimization of the scaffold. With a general objective of reducing topological polar surface area, and guided by multiple metabolite identification studies, we were successful at identifying 17 (CCG-222628), which achieves remarkably greater brain exposure in mice than 2. After demonstrating an over 60-fold improvement in potency over 2 at reducing brain GlcCer in normal mice, we compared 17 with Sanofi clinical candidate venglustat (Genz-682452) in the CBE mouse model of Gaucher disease type 3. At doses of 10 mg/kg, 17 and venglustat effected comparable reductions in both brain GlcCer and glucosylsphingosine. Importantly, 17 achieved these equivalent pharmacodynamic effects at significantly lower brain exposure than venglustat.

IMPROVED PROCESS FOR THE PREPARATION OF ELIGLUSTAT AND ITS SALTS

The present application relates to an improved process for the preparation of Eliglustat or its pharmaceutically acceptable salts thereof. Further relates to isolation of intermediates in the form of solid and their use for preparation of Eliglustat or its pharmaceutically acceptable salts thereof.

IMPROVED PROCESS FOR THE PREPARATION OF ELIGLUSTAT

The present invention provides an improved process for the preparation of eliglustat to salts thereof. Present invention also provides a crystalline eliglustat free base form R1.